The total return over the past 12 months is -40.68% vs. +16.94% for the S&P 500. So far it's up +0.78% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (40.70%) | (94.54%) | (91.63%) | N/A | N/A | N/A |
| Total Return CAGR | (40.68%) | (94.54%) | (91.63%) | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
CNS Pharmaceuticals, Inc. (CNSP)
| Year | Start price | End price | CNSP Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $5.25 | $5.30 | +0.78% | +14.51% | (13.73%) |
| 2025 | $72.24 | $5.25 | (92.71%) | +17.72% | (110.43%) |
| 2024 | $38,100.00 | $72.24 | (99.81%) | +24.89% | (124.70%) |
| 2023 | $72,000.00 | $38,100.00 | (47.08%) | +26.19% | (73.27%) |
| 2022 | $632,160.00 | $72,000.00 | (88.61%) | (18.17%) | (70.44%) |
| 2021 | $1,602,000.00 | $632,160.00 | (60.54%) | +28.74% | (89.28%) |
| 2020 | $3,555,000.00 | $1,602,000.00 | (54.94%) | +18.37% | (73.31%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
